Is this what you meant @LawyerTrader ?
The new impella is game changer according to ABIOSE1 providing ABIO the nano size fluid sensor.
- Beginning with innovation, the Impella 5.5 with SmartAssist continues to perform very well. In the quarter, our U.S surgical revenue grew 115% year-over-year and 17% versus prior quarter as we expanded this life saving device to 46 more sites or 257 sites out of the 1,113 heart hospitals in total.
- Impella 5.5 is a revolutionary product. It does not require a sternotomy or coring of the left ventricle and it is a forward flow, fully unloading weanable heart pump designed for heart surgeons to implant in less than 60 minutes via the axillary artery in the shoulder. The minimally invasive implant also allows for early ambulation for the patient, which correlates to faster recovery and better outcomes.
- The longer usage time for the Impella 5.5 allows the SmartAssist software to track aortic pressure, left ventricular pressure, make predictive analysis on volume and right heart stability, and communicate in the cloud with Impella Connect. We look forward to continuing to roll this device out to the remaining 856 heart hospitals in the U.S., and many more outside the U.S.
- Forums
- ASX - By Stock
- SE1
- Ann: Sensera completes A$2.5m private placement
Ann: Sensera completes A$2.5m private placement, page-109
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)